OK
OKYO.US OKYO Pharma Limited
- Market cap
- USD 70.8M
- P/E
- -
- P/B
- 5.70x
- ROE
- -206.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is OKYO.US undervalued?
Graham numberThe Graham number of OKYO Pharma Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
OKYO Pharma Limited fundamental analysis
No fundamental analysis for OKYO Pharma Limited yet.
OKYO Pharma Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About OKYO Pharma Limited
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Full company profileOKYO Pharma Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
OKYO Pharma Limited annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | - | - | -219.00 | -5.97K | -811K | -13.0K | -6.75M | -7.51M | -2.56K | -6.69M | -3.74K |
| Operating Income | -363K | -28.3M | -4.54M | -1.52M | -4.13M | -6.23M | -13.1M | -15.7M | -7.19M | -8.50M | -25.6M |
| EBITDA | -363K | 1.04M | -4.54M | -1.49M | -4.12M | -6.22M | -13.1M | -15.7M | -7.08M | -8.47M | -25.6M |
| Net Income | -242K | -28.3M | -4.90M | -1.54M | -3.35M | -5.43M | -13.3M | -16.8M | -4.71M | -8.95M | -25.5M |
| EPS | -0.04 | -4.80 | -0.62 | -0.17 | -0.32 | -0.36 | -0.60 | -0.57 | -0.12 | -0.24 | -0.68 |
| Balance Sheet | |||||||||||
| Total Assets | 27.8M | 2.01M | 760K | 597K | 7.09M | 4.30M | 5.20M | 1.54M | 3.68M | 21.0M | 21.0M |
| Total Liabilities | 259K | 91.1K | 427K | 737K | 1.77M | 1.35M | 7.26M | 7.42M | 9.23M | 8.64M | 8.64M |
| Shareholders' Equity | 27.5M | 1.92M | 333K | -140K | 5.32M | 2.95M | -2.05M | -5.88M | -5.55M | 12.3M | 12.3M |
| Cash & Short-term Investments | 16.9M | 2.01M | 628K | 235K | 6.89M | 2.70M | 4.05M | 827K | 1.56M | 20.6M | 20.6M |
| Total Debt | - | - | - | 25.6K | 98.8K | - | 2.22M | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -651K | -1.59M | -1.99M | -1.20M | -1.60M | -5.47M | -7.70M | -9.49M | -1.81M | -5.94M | -17.6M |
| Capital Expenditure | 375K | 1.01K | 1.32K | 5.03K | 6.94K | 1.67K | 5.92K | 3.00 | 1.21K | 6.08K | 24.3K |
| Free Cash Flow | -1.03M | -1.59M | -1.99M | -1.20M | -1.61M | -5.47M | -7.70M | -9.49M | -1.81M | -5.94M | -17.7M |
| Ratios | |||||||||||
| ROE | -0.9% | -1,476.4% | -1,469.4% | - | -63.1% | -184.3% | - | - | - | -72.6% | -206.3% |
| ROA | -0.9% | -1,409.4% | -644.2% | -258.1% | -47.3% | -126.3% | -255.0% | -1,091.7% | -128.0% | -42.7% | -121.3% |
| Debt to Equity | - | - | - | - | 0.02x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
OKYO Pharma Limited dividends
OKYO Pharma Limited has not paid dividends in the last 9 fiscal years.
Who owns OKYO Pharma Limited
- Insiders 31.13%
- Institutions 18.53%
- Public & others 50.34%
- Shares outstanding 52.5M
- Free float 27.9M
Top funds holding OKYO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 12.1K | 0.02% | 0.00% | Aug 2026 |
Top institutions holding OKYO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Woodline Partners LP | 3.65M | 6.96% | +0.02% | Jun 2026 |
| Stonepine Capital Management Llc | 863K | 1.64% | +1.53% | Jun 2026 |
| MAVEN SECURITIES Ltd | 809K | 1.54% | -31.15% | Jun 2026 |
| Balyasny Asset Management LLC | 581K | 1.11% | -0.72% | Jun 2026 |
| Opaleye Management Inc | 375K | 0.72% | 0.00% | Jun 2026 |
| UBS Group AG | 55.0K | 0.10% | -7.95% | Jun 2026 |
| XTX Topco Ltd | 37.8K | 0.07% | +0.31% | Jun 2026 |
| Quantinno Capital Management LP | 33.3K | 0.06% | 0.00% | Jun 2026 |
| RSM US WEALTH MANAGEMENT LLC | 33.3K | 0.06% | 0.00% | Jun 2026 |
| HPM Partners LLC | 12.8K | 0.02% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 12.1K | 0.02% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 10.3K | 0.02% | 0.00% | Jun 2026 |
| Steward Partners Investment Advisory, LLC | 6.00K | 0.01% | 0.00% | Jun 2026 |
| EFG International AG | 923.00 | 0.00% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 152.00 | 0.00% | 0.00% | Jun 2026 |
| Continuum Advisory, LLC | 50.00 | 0.00% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 10.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 3.00 | 0.00% | 0.00% | Jun 2026 |
| Dauntless Investment Group, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Renaissance Technologies Corp | 0.00 | 0.00% | -100.00% | Sep 2026 |
OKYO Pharma Limited company profile
- Company name
- OKYO Pharma Limited
- Ticker
- OKYO.US
- ISIN
- GG00BMFG5F62
- Exchange
- USA Stocks
- Listed since
- May 17, 2022
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Fiscal year end
- March
- Address
- 35a Albemarle St, London, United Kingdom, W1S 4JE
- Phone
- 44 20 7495 2379
- Website
- okyopharma.com
About OKYO Pharma Limited
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
OKYO Pharma Limited management
6- Mr. Robert J. Dempsey M.B.A.CEO & Executive Director
- Ms. Keeren ShahChief Financial Officer · born 1976
- Dr. Rajkumar Patil Ph.D.Chief Scientific Officer · born 1959
- Dr. Gary S. Jacob Ph.D.Chief Development Officer & Director · born 1947
- Dr. Flavio Mantelli M.D., Ph.D.Chief Medical Officer
- Mr. Michael Paul BeckFounder · born 1957